These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30069634)

  • 1. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
    Hewett YG; Uprety D; Shah BK
    J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
    Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
    J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
    Brown JR
    Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
    Krause G; Hassenrück F; Hallek M
    Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
    Keating GM
    Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
    J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species.
    Akhiani AA; Hallner A; Kiffin R; Aydin E; Werlenius O; Aurelius J; Martner A; Thorén FB; Hellstrand K
    Cancer Immunol Res; 2020 Dec; 8(12):1532-1541. PubMed ID: 32967913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
    Davies A
    Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
    Pongas G; Cheson BD
    Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
    Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
    Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
    Front Immunol; 2021; 12():608625. PubMed ID: 33790890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idelalisib for treatment of B-cell malignancies.
    Do B; Mace M; Rexwinkle A
    Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.